Tenaya Therapeutics, Inc. (NasdaqCM: TNYA)
Health Care · Biotechnology · US
$0.66
-5.18% today · -34.8% 1Y
Tenaya Therapeutics, Inc. (NasdaqCM: TNYA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $156.36M and employs 70 people.
Over the last twelve months the share price has lost 34.8%, trading between 0.53 and 2.35.
Tweenvest scores Tenaya Therapeutics, Inc. across four factors: quality 28/100, value 59/100. Its strongest factor is value.
TNYA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $156.36M
- Revenue (TTM)
- $1.33M
- P/E
- —
- EPS
- -0.53
- Dividend yield
- —
- Beta (5Y)
- 2.79
- 52-week high
- $2.35
- 52-week low
- $0.53
- Avg volume (3M)
- —
- Shares outstanding
- 224.23M
- Employees
- 70
- Next earnings
- —
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- ISIN
- US87990A1060
- Founded
- 2016
- Listed since
- Jul 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.